Journal of Bioequivalence & Bioavailability

William DeMaio

Publications

• Research Article
  Metabolism Studies of Desvenlafaxine
  Author(s): William DeMaio, Cecelia P. Kane, Alice I. Nichols and Ronald JordanWilliam DeMaio, Cecelia P. Kane, Alice I. Nichols and Ronald Jordan
  
  Background: This series of experiments was conducted to describe the metabolic profile of the serotonin norepinephrine reuptake inhibitor desvenlafaxine (administered as desvenlafaxine succinate) using animal and human models. Methods: In vivo and in vitro experiments were conducted with humans and preclinical species (CD-1 mice, Sprague Dawley rats, and beagle dogs). Single oral doses of [14C]-desvenlafaxine were administered to each preclinical species for analyses of desvenlafaxine concentration in plasma, urine, and feces. Rats also were subjected to whole body autoradiography and quantitative tissue sampling. The major UDP-glucuronosyltransferase (UGT) isoforms involved in the formation of desvenlafaxine-O-glucuronide were also assessed. In vivo human experiments were conducted with healthy volunteers administered desvenlafaxine 100, 300, or 600 mg, followed by 72 hours of plas.. View More»
  DOI: 10.4172/jbb.1000076

  Abstract PDF